(Q41121162)

27 September 2017

1 reference

title

Recent developments in antifungal therapy (English)

1 reference

27 September 2017

Lesher JL Jr

1

1 reference

27 September 2017

1 January 1996

1 reference

27 September 2017

1 reference

27 September 2017

14

1 reference

27 September 2017

1

1 reference

27 September 2017

163-169

1 reference

Ciclosporin A and Griseofulvin: Another Drug Interaction

27 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Azoles, a48 llylamines and drug metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

New approaches to the diagnosis and management of onychomycosis. International Symposium, Monaco, April 1-2, 1993.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Topical terbinafine and clotrimazole in interdigital tinea pedis: a multicenter comparison of cure and relapse rates with 1- and 4-week treatment regimens.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Antifungal therapy: potential interactions with other classes of drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Costs of therapy for dermatophyte infections

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Persistent Candida intertrigo treated with fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Interaction of griseofulvin and oral contraceptives

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double-blind, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Itraconazole in opportunistic mycoses: cryptococcosis and aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Tinea capitis: itraconazole in Trichophyton tonsurans infection

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

One-week therapy with oral terbinafine in cases of tinea cruris/corporis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

An unusual case of severe griseofulvin-alcohol interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Pharmacokinetics of terbinafine in the nail

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Tinea capitis: epidemiology, diagnosis, treatment, and control.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Epidemiology and treatment of tinea capitis: ketoconazole vs. griseofulvin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Antifungal agents: an overview. Part II.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-inflammatory tinea capitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Onychomycosis. Agents of choice.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Treatment of cutaneous sporotrichosis with terbinafine.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Fatal acute hepatic necrosis due to fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Loss of taste and terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Itraconazole Compared with Griseofulvin in the Treatment of Tinea corporis/cruris and Tinea pedis/manus: An Interpretation of the Clinical Results of all Completed Double-Blind Studies with Respect to the Pharmacokinetic Profile

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Hepatic injury associated with itraconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Itraconazole in the treatment of tinea capitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Antifungal agents in dermatology

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Effect of Terbinafine on the Pharmacokinetics of Cyclosporin in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized study in children

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Hepatitis associated with terbinafine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Itraconazole penetrates the nail via the nail matrix and the nail bed--an investigation in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Onychomycosis: successful treatment with once-weekly fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Terbinafine in onychomycosis with involvement by non-dermatophytic fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Double-blind comparison of itraconazole and placebo in the treatment of tinea corporis and tinea cruris

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

New approaches to the treatment of onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Debilitating edema associated with itraconazole therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Terbinafine: mode of action and properties of the squalene epoxidase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Stevens-Johnson syndrome after terbinafine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Successful treatment of Aspergillus flavus onychomycosis with oral itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Itraconazole treatment of phaeohyphomycosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Are laboratory studies necessary for griseofulvin therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Single dose treatment of fungal nail disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

A case of chromoblastomycosis responding to treatment with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Treating tinea capitis: should ketoconazole replace griseofulvin?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Interaction of Azoles with Rifampin, Phenytoin, and Carbamazepine: In Vitro and Clinical Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

A randomized treatment duration-finding study of terbinafine in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Special features of the clinical use of oral terbinafine in the treatment of fungal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970337-5

7 January 2021

10.1016/S0733-8635(05)70337-5

Identifiers

DOI

1 reference

27 September 2017

1 reference

PubMed ID

8821170